Market Overview - On June 19, A-shares opened lower and continued to decline, with the Shanghai Composite Index falling by 0.79% to 3362 points, the Shenzhen Component Index down by 1.21%, and the ChiNext Index down by 1.36%, with over 4600 stocks declining across the market [1] - Market focus shifted towards the oil, natural gas, and digital reading sectors [1] High-Performing Stocks - In the oil and gas sector, Zhuan Oil Co. and Shandong Molong achieved five consecutive trading limits, while military stock Beifang Changlong saw a 20% increase over three days [3] - Notable stocks with significant gains include: - Shandong Quanlong: +10.00%, five consecutive limits [4] - Zhuan Oil Co.: +9.96%, five consecutive limits [4] - Beifang Changlong: +20.01%, three limits in five days [4] - Innovation Medical: +10.04%, two limits in three days [4] Trading Activity - The top three net purchases on the Dragon and Tiger list were: - Innovation Medical: net purchase of 207 million [5] - Electric Science Cybersecurity: net purchase of 153 million [5] - Anni Co.: net purchase of 135 million [5] - The top three net sales were: - Limin Co.: net sale of 230 million [7] - Xiexin Energy: net sale of 218 million [7] - Changshan Pharmaceutical: net sale of 178 million [7] Sector Highlights - Innovation Medical focuses on brain-machine interfaces and AI medical models, achieving a trading limit with a turnover of 1.745 billion and a turnover rate of 31.78% [10] - Baida Qiancheng, involved in short drama games and major contract signings, also reached a trading limit with a turnover of 1.077 billion [14] - Electric Science Cybersecurity, which focuses on digital currency and satellite navigation, achieved a trading limit with a turnover of 694 million [18] Institutional Activity - Institutions showed significant interest in several stocks, with net purchases in: - Electric Science Cybersecurity: 35 million [22] - Innovation Medical: 26 million [22] - Shandong Molong: 20 million [22] - Conversely, institutions sold off stocks like Limin Co. and Xiexin Energy, with net sales of 64 million and 71 million respectively [19][22] Conclusion - The market experienced a downward trend with specific sectors like oil and gas showing resilience through notable stock performances. Institutional trading patterns indicate selective interest in high-growth potential stocks, particularly in the technology and healthcare sectors.

Group 1 - Chengjian Development received a dividend of 7.1282 million yuan from Beijing Jingcheng Jiaye Property Co., Ltd., in which it holds a 33.47% stake [1] - Shengnuo Bio expects a net profit attributable to shareholders of 77.0275 million to 94.1448 million yuan for the first half of 2025, representing a year-on-year increase of 253.54% to 332.10% [1] - JKN2301 dry mixed suspension has been approved for clinical trials, targeting children with influenza [5][6] Group 2 - Jindawei obtained a patent for a method of purifying natto kinase, with a validity of twenty years [2] - CITIC Guoan plans to increase its stake in China Broadcasting Hunan Company to approximately 5.29% through a capital increase of 278 million yuan [2] - Ji Electric announced the resignation of its general manager, Niu Guojun, due to work changes [3] Group 3 - Xintian Green Energy successfully issued 1.5 billion yuan in green medium-term notes with a term of 3+N years and an interest rate of 2.05% [7] - Hengrun Co. plans to invest 1.2 billion yuan in a project to produce 2,000 sets of wind turbine gearbox components [9] - Pulaide received a government subsidy of 10 million yuan, accounting for 15.87% of its audited net profit for the last fiscal year [10] Group 4 - Boteng Co. passed the EU QP audit, receiving a compliance statement for its CDMO services [12] - Zhou Dasheng added 7 self-operated stores in May, with total investments ranging from 900,000 to 6.5 million yuan [13] - Wantai Bio initiated a Phase III clinical trial for its live attenuated varicella vaccine [15] Group 5 - Shanghai Pharmaceuticals received a drug registration certificate for Pregabalin capsules in Thailand [19] - Sanxing Medical's subsidiary is expected to win contracts worth approximately 143 million yuan from State Grid projects [21] - Jiangsu Huachen plans to issue 460 million yuan in convertible bonds [24] Group 6 - Jian Gong Repair won a soil pollution remediation project worth 32.76 million yuan [25] - Dize Pharmaceutical completed patient enrollment for a global Phase III clinical trial of its drug [26] - Del Co. received acceptance for its application to issue shares for asset acquisition and raise matching funds [27] Group 7 - Beijing Kerui won multiple power grid projects with a total value of approximately 154 million yuan [27] - Xie Chuang Data signed financing lease contracts totaling 498 million yuan with Su Yin Financial Leasing [28] - Meige Intelligent submitted an application for H-share listing on the Hong Kong Stock Exchange [29][31] Group 8 - Aikodi plans to repurchase shares worth 100 million to 200 million yuan for employee stock ownership plans [54] - Kong Kong Industrial intends to sell 80% of Tianyuan Construction to its controlling shareholder [55] - Youyou Green Energy proposed a cash dividend of 12 yuan per 10 shares, totaling 50.4 million yuan [55]

随着医疗需求来越越多元化和个性化，非急救转运以及跨省转 运的使用场景会越来越多，这意味着，非急救转运服务体系亟 待完善。近年来，多地都在探索建立规范化的非急救转运服务 体系。 作者： 言咏 封图：图虫创意 通报中提到"就诊医院无符合跨省转运条件的救护车"，这亦是公众关切之处。患儿家属表示，当时 也觉得费用昂贵，但情况紧急，不容多考虑。这是人之常情。孩子病情危重，做父母的但凡拿得出 钱来都不会退却。可以说，这种"同意"并非基于完全平等的自由议价，带有很强的无奈，也反映出 医疗转运服务体系的短板。公众不禁要问：就诊医院为何没有符合跨省转运条件的救护车？除了民 营救护车，还有其他更平价的选择吗？2.8万元不是一个小数目，不是谁都花得起。如果花不起， 家属要如何抉择呢？ 中国公立系统的救护车很少执行跨省转运业务，是因为制度限制、资源分配和职能划分等多重因 素。我国救护车服务分院前急救和非急救转运两类。院前急救由公立系统负责，多为属地化管理， 主要服务辖区内急救需求，很少用于跨省转运；非急救转运则多由民营机构运营。根据《院前医疗 急救管理办法》，前者不得用于非院前医疗急救服务。这一制度设计旨在平衡急救资源的公益性和 使 ...

（原标题：救护车收费2.8万 江西通报未解公众关切） 言咏 | 文 针对江西一位父亲对救护车转运其重症孩子时800公里收费2.8万元的投诉，6月18日，江西省 卫健委连夜发布了情况通告。通告认定救护车所有方南昌赣医医院存在收费不合理等问题，卫生健康行 政部门已责令其退回不合理收费，并暂停其医疗转运服务。下一步，江西卫健委将联合相关职能部门对 事件进一步调查核查。 根据通报，这位患儿今年4月在江西省儿童医院心脏重症监护室紧急救治，因病情危重，4月8日19时20 分家属提出急需连夜转运治疗。由于就诊医院无符合跨省转运条件的救护车，经家属请求，诊治医生联 系了赣医医院的救护车。救护车司机与家属沟通，约定转运费2.8万元，分两次支付。江西省儿童医院 派出两名医护人员随车护送，并携带使用ECMO（体外膜肺氧合）等相关抢救设备和药品。4月9日5时 许，救护车到达家属指定的上海某医院紧急救治，患儿转危为安。 通报中提到"就诊医院无符合跨省转运条件的救护车"，这亦是公众关切之处。患儿家属表示，当时也觉 得费用昂贵，但情况紧急，不容多考虑。这是人之常情。孩子病情危重，做父母的但凡拿得出钱来都不 会退却。可以说，这种"同意"并非 ...

Core Viewpoint - The "2025 Health China Innovation Practice Case Collection and Display Activity" has been officially launched to promote innovative practices and advanced experiences in health management and patriotic health movements across various regions and units [1] Group 1: Collection Details - The collection is open to the entire society, including government bodies, public hospitals, schools, research institutions, social organizations, and enterprises [2] - The collection period is from now until September 20, 2025 [3] Group 2: Collection Content - Cases related to health weight management, focusing on innovative management measures and typical experiences in implementing weight management systems [3] - Cases related to medical foundation projects, emphasizing innovations in rural health construction, county medical capacity enhancement, and community health services [3] - Cases in health digitalization and technology transfer, including applications of AI in diagnosis, digital hospital construction, and telemedicine services [3] - Cases in traditional Chinese medicine health initiatives, focusing on cultural literacy, service improvements, and non-drug therapies [4] Group 3: Case Requirements - The submitted cases must be based on real examples, avoiding fabrication or exaggeration [5] - Cases should be typical and provide meaningful solutions that can serve as references for other regions [6] - Submissions must include background, specific measures, and results, supported by data or charts [6] - The logic, methods, and technical solutions in the cases must adhere to scientific principles and comply with policies and ethics [6] Group 4: Submission Method - Cases should be submitted via email, with a specific subject format and additional materials allowed [8] - Contact information for inquiries is provided, including names and phone numbers [8] Group 5: Application of Case Results - Selected cases will be showcased on the People's Health platform [9] - Invited units will participate in case research and exchange to promote results [9] - Eligible cases may become partners in the People's Daily data intelligence program for deeper collaboration [9]

Company Overview - PACS Group, Inc. shares increased by 21.8% to close at $12.35, with trading volume significantly higher than usual, contrasting with a 6.2% loss over the past four weeks [1] - The company is undergoing an audit committee investigation, which is nearly complete, and no integrity issues have been found regarding top management [2] Financial Performance - PACS Group is expected to report quarterly earnings of $0.42 per share, reflecting a year-over-year increase of 10.5%, with revenues projected at $1.09 billion, up 16.5% from the previous year [3] - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, indicating stability in earnings expectations [4] Industry Context - PACS Group operates within the Zacks Medical Services industry, where Sotera Health Company, a peer, has seen a 3.3% decline in its stock price recently and a negative return of 11.6% over the past month [4] - Sotera Health's consensus EPS estimate has also remained unchanged, currently at $0.17, which is a decrease of 10.5% compared to the previous year [5]

新京报讯（记者戴轩）6月18日，北京大学第三医院海淀北部院区（北医三院海淀北部院区）正式开 诊，标志着海淀区北部医疗中心建设迈入新阶段。此次率先开放门诊服务，急诊和住院服务根据规划陆 续启用。 开诊当天，北医三院海淀北部院区在门诊大厅举行了大型义诊活动，来自心血管内科、呼吸与危重症医 学科、内分泌科、血液内科、消化科、老年内科、神经内科、皮肤科、中医科、普通外科、骨科、神经 外科、运动医学科、康复医学科等14个科室的专家为居民提供免费诊疗服务。 北医三院海淀北部院区位于北京市海淀区六里屯南路6号院，占地面积9600余平方米，规划总床位400 张，所有出诊专家均来自北医三院本部。 院区配备先进的医疗设备，构建覆盖门（急）诊、检验检查、住院、手术等多学科的综合诊疗体系，为 各类疾病诊治和危急重症救治提供必要保障。同时，北医三院海淀北部院区将全面部署电子病历、移动 支付、线上复诊等智慧医疗应用，深入探索智慧院区建设。 北医三院海淀北部院区首批开放临床科室包括： 内科系统科室：心血管内科、呼吸与危重症医学科、内分泌科、肾内科、血液内科、消化科、老年内 科、神经内科、皮肤科、中医科、肿瘤放疗科、全科医学科等。 外科系统 ...

Core Viewpoint - The article discusses the emerging field of proton and heavy ion therapy as a cutting-edge cancer treatment, highlighting its advantages over traditional radiation therapy, while also addressing the challenges of high costs and limited accessibility for patients [1][2][3]. Group 1: Treatment Overview - Proton and heavy ion therapy utilizes charged particles to target and destroy tumor cells, offering benefits such as reduced side effects and higher tumor control rates compared to conventional radiation therapy [1][3]. - Clinical studies indicate that particle therapy has a five-year overall survival rate of nearly 70% for patients, with specific rates of 92.9% for nasopharyngeal cancer and 70.3% for early-stage non-small cell lung cancer [1][2]. Group 2: Accessibility and Costs - The treatment costs approximately 300,000 yuan per course, which is not covered by health insurance, making it unaffordable for many patients [2][6]. - Only a few thousand patients receive proton and heavy ion therapy annually in China, compared to over 4 million new cancer cases each year, indicating a significant gap in treatment availability [2][6]. Group 3: Technological Development - China has made rapid advancements in proton and heavy ion therapy since the establishment of its first treatment center in 2015, with ongoing efforts to expand the number of treatment facilities [8][9]. - The high cost of equipment and treatment, along with the complexity of the therapy process, limits the number of patients that can be treated each year, with estimates of 1,000 to 1,500 cases annually per facility [10][11]. Group 4: Insurance and Financial Solutions - Approximately 60% of patients self-fund their treatment, while commercial health insurance covers nearly 40% of the costs, highlighting the financial burden on families [15][16]. - Initiatives like the "Shanghai Health Insurance" program include proton and heavy ion therapy, assisting patients with insurance claims and improving treatment accessibility [16][17].

Core Viewpoint - The article highlights the launch of a free fluoride application program for new kindergarten children in Yuhang District, aimed at improving children's oral health and preventing dental caries [1] Group 1: Program Overview - The fluoride application initiative covers 159 kindergartens in Yuhang District, targeting approximately 11,000 new children [1] - This marks the third year of the fluoride application program, indicating a sustained effort in promoting children's oral health [1] Group 2: Training and Awareness - Prior to the program, 12 community health service centers trained medical staff in standardized techniques for fluoride application [1] - The initiative includes educational outreach to parents, enhancing their understanding and acceptance of fluoride treatments [1] Group 3: Parental Engagement - Parents, such as Ms. Zheng, expressed initial concerns about the safety of fluoride materials but became more informed through educational resources provided by the school [1] - Increased parental acceptance and cooperation have been noted compared to the first year of the program, reflecting the effectiveness of educational efforts [1] Group 4: Future Plans - The district plans to continue and expand the fluoride application program, incorporating more oral health education activities in kindergartens [1] - The goal is to ensure that more children benefit from quality oral health services, supporting their healthy development [1]

在临平，得益于完善的早孕关爱服务，越来越多像刘女士这样的女性正通过早孕门诊获得专业服务 和人文关怀。据了解，早孕门诊主要服务于以妊娠为主诉的孕早期女性，为拟生育、早孕异常、拟人工 流产三类人群提供针对性指导和精准规范的诊疗服务。 目前，临平区已构建起完善的"1+2+N"早孕关爱服务网络，即以1家省级监测医院（临平区妇幼保 健院）为核心，2家市级监测医院（临平区第一人民医院、临平区中医院）为骨干，并在全市率先将符 合条件的民营助产医院及社区卫生服务中心纳入服务网络，形成了"20分钟早孕关爱服务圈"。 临平区卫健局相关负责人介绍，早孕门诊的核心优势在于其整合了妇产科、内外科、营养科、中医 科等多学科优质诊疗资源，为早孕女性提供"咨询—评估—管理—转诊"的全链条服务。目前，临平共有 11家医疗机构开设了早孕门诊，今年以来已累计为1500余名女性提供早孕关爱服务。 今后，临平区将继续秉持"怀得上、留得住、孕得优"的理念，深化早孕门诊建设，在充分尊重女性 及家庭意愿的基础上，以专业力量筑牢优生优育根基，为杭州市基层早孕门诊提供"临平样本"。 临平区中医院早孕门诊 近日，顺利通过胎儿NT（颈项透明层）检查的刘女士安心了不 ...